Sai Life Sciences Limited Receives GST Order with Demand of INR 16.28 Crores Plus Interest and Penalty

1 min read     Updated on 01 May 2026, 01:57 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Sai Life Sciences Limited disclosed receipt of a GST order dated 29 April 2026 with demand of INR 16,28,46,397, interest of INR 13,31,50,353, and penalty of INR 3,25,69,279 related to financial year 2021-22. The company plans to appeal and expects no material financial impact.

powered bylight_fuzz_icon
39169676

*this image is generated using AI for illustrative purposes only.

Sai Life Sciences Limited has informed the stock exchanges about receipt of a Goods and Services Tax (GST) order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi. The order was passed on 29 April 2026 at 11:32 AM under Section 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka Goods and Services Tax Act, 2017.

Details of the GST Order

The order raises a demand concerning alleged excess availment of input tax credit in GSTR-3B than available in GSTR-2A for the financial year 2021-22. The tax authority has specified the following amounts:

Component Amount (INR)
IGST Demand 16,28,46,397
Interest 13,31,50,353
Penalty 3,25,69,279

Company's Response

According to the disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Life Sciences Limited stated that based on its assessment, an appeal will be filed against the order. The company expressed hope for a favourable outcome at the Tribunal level and indicated that it does not reasonably expect the said order to have any material financial impact on its operations.

The disclosure was signed by Runa Karan, Company Secretary & Compliance Officer, and submitted to both the National Stock Exchange of India Limited and BSE Limited on 30 April 2026.

Historical Stock Returns for Sai Life Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.36%+6.31%+8.48%+16.66%+49.72%+39.86%

How might this GST dispute affect Sai Life Sciences' credit rating and access to financing during the appellate process?

What potential impact could this case have on GST compliance practices across the pharmaceutical industry?

Will Sai Life Sciences need to provide bank guarantees or deposits while appealing, and how might this affect their working capital?

Sai Life Sciences Allots 2,44,281 Equity Shares Under Employee Stock Option Plans

1 min read     Updated on 26 Apr 2026, 03:57 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Sai Life Sciences Limited allotted 2,44,281 equity shares under ESOP 2008 and MESOP 2018 on 23 April 2026, comprising 44,500 shares at Rs. 188.90 and 1,99,781 shares at Rs. 127.30 respectively. The company raised INR 3,38,38,171.30 through this exercise, increasing total issued shares to 21,20,23,515. The allotment supports employee retention while strengthening the company's capital base.

powered bylight_fuzz_icon
38744869

*this image is generated using AI for illustrative purposes only.

Sai Life Sciences Limited has completed the allotment of 2,44,281 fully paid-up equity shares under its employee stock option plans on 23 April 2026. The Board of Directors approved the allotment of shares upon exercise of options granted under the company's ESOP 2008 and MESOP 2018 schemes.

Share Allotment Details

The allotment was executed under two separate employee stock option plans with different pricing structures:

Plan: Shares Allotted Exercise Price (Rs.) Premium (Rs.)
ESOP 2008: 44,500 188.90 187.90
MESOP 2018: 1,99,781 127.30 126.30
Total: 2,44,281 - -

All shares carry a par value of Re.1 per share and have been issued in dematerialized form with distinctive numbers ranging from 211779235 to 212023515. The shares are identical in all respects to the existing equity shares of the company.

Financial Impact

The exercise of these stock options generated INR 3,38,38,171.30 for the company. This amount represents the total consideration received from employees who exercised their vested options under both schemes. The funds raised through this allotment will contribute to the company's working capital requirements.

Updated Share Capital Structure

Following this allotment, the company's capital structure has been updated as follows:

Parameter: Details
Total Issued Shares: 21,20,23,515
Total Issued Share Capital: Rs. 21,20,23,515
ISIN: INE570L01029
Lock-in Details: Not Applicable

ESOP Scheme Framework

Both ESOP plans are designed to attract, retain and reward employees while contributing to the company's growth. The schemes feature a maximum vesting period of 5 years with multiple vesting options. The exercise period extends until the employee remains in service with the company, providing flexibility for option holders to exercise their rights based on market conditions and personal financial planning.

The company has filed the necessary regulatory disclosures with BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring full compliance with listing requirements.

Historical Stock Returns for Sai Life Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.36%+6.31%+8.48%+16.66%+49.72%+39.86%

How will the INR 3.38 crore raised from ESOP exercises impact Sai Life Sciences' planned capital expenditure and R&D investments?

What percentage of outstanding ESOP options remain unexercised across both schemes, and when do they expire?

Will the company consider launching new employee stock option schemes given the apparent success of the current programs?

More News on Sai Life Sciences

1 Year Returns:+49.72%